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ABSTRACT
Objective: The objective of the work is to formulate nizatidine mucoadhesive matrix tablets which will significantly improve the bioavailability of 
drugs under the condition of prolonged use of drugs and reduce the total dosage of administered drug and reduce the side effect.
Method: Matrix tablet was prepared by direct compression of polymer such as HPMC K4M, carbopol-934p, and ethyl cellulose alone and in combination.
Result: After analysis of different evaluation parameter and drug release, F9 batch was selected as promising formulation for delivery of nizatidine as 
a mucoadhesive matrix tablet with 94.18% drug release at the 12th h.
Conclusion: It was observed that the combination of both polymers in equal concentration gives the best drug release and sustains the drug release for 
12 h. Among the other batches, F9 batch was selected as an optimized batch because the pre- and post-compression parameter results are satisfactory.
Keywords: Nizatidine, Mucoadhesive matrix tablet, HPMC K4M, Carbopol-934p, Ethyl cellulose.
INTRODUCTION
Oral route is the most convenient and the most commonly implemented 
route for drug delivery. Oral route of administration has been receiving 
more attention in pharmaceutical field because of the more flexibility 
in the designing of dosage form than drug delivery design for other 
routes. The oral drug delivery depends on various factors such as the 
type of delivery system, the disease being treated, and the patient, 
the length of the therapy, and the properties of the drug [1]. The 
controlled or sustain drug delivery attempts to sustain drug action at 
a predetermined rate by maintaining relatively constant and effective 
drug levels in the body with minimization of undesirable side effects. 
It also provides localized drug action by spatial placement of the 
sustained release system [2,3].
Nizatidine is a Class III drug, i.e. high-solubility, low-permeability 
compound [Fig. 1]. Nizatidine has short biological half-life (1–2 h) and 
susceptible to metabolism by colonic bacteria. It has been reported that 
the local delivery of H2-receptor antagonists increases the stomach 
wall receptor site bioavailability and increases efficacy of these drugs 
to reduce acid secretion [4].
Bioadhesion is an attachment of macromolecules that are synthetic 
or natural to mucus or the surface of the epithelium. This utilizes 
the bioadhesion property which adheres on hydration due to certain 
polymers and hence used for drug targeting at an exacting area for 
an extensive period of time in the body. When applied to mucosal 
epithelium, bioadhesive interactions occur primarily with the mucus 
layer and this phenomenon is referred to as mucoadhesion [5].
Matrix tablet formulations have been widely accepted oral controlled 
drug delivery formulations because of its simple nature, ease in the 
formulation process, highly reproducible, stability of the raw materials 
and dosage form, ease of scale-up, and process validation. The matrix 
system is the mixture of materials with the drug, which will cause the 
drug to slow down. However, this system has several subcategories: 
Hydrophobic matrices, lipid matrices, hydrophilic matrices, 
biodegradable matrices, and mineral matrices [6].
Advantages of bioadhesive drug delivery systems[7]
a. A prolonged residence time at the site of action or absorption,
b. A localization of the drug delivery system at a given target site,
c. An increase in the drug concentration gradient due to the intestine 
contact of the particles with the mucosal surface,






Nizatidine was a gift sample from Zhejiang Medicine & Health 
Products Import & Export Co., Ltd., China. HPMC K4M were procured 
from Chemdyes Corporation, Gujarat. Carbopol-934p were procured 
from Research-Lab Fine Chem Industries, Mumbai. Ethyl cellulose, 
microcrystalline cellulose, and magnesium stearate were procured 
from Thomas Baker Pvt. Ltd, Mumbai. All reagents used were of 
analytical grade.
METHODS
Drug excipient compatibility studies[8]
Fourier-transform infrared (FT-IR) spectrum matching approach 
was used for detection of any possible chemical interaction between 
nizatidine and polymers. IR spectroscopy was conducted using a 
FT-IR spectrophotometer (Jasco FT-IR 410), and the spectrum was 
recorded in the wavelength region of 4000–400 cm−1. The procedure 
consisted of dispersing a sample (drug alone or mixture of drug and 
excipients) in KBr and compressed into discs by applying a pressure 
of 5 tons for 5 min in a hydraulic press. The pellet was placed in the 
light path and the spectrum was obtained. Samples were prepared 
for nizatidine, polymers such as ethyl cellulose, carbopol-934, HPMC 
K4M, and physical mixture of drug with polymers. The spectra 
obtained were compared and interpreted for the functional group 
peaks.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i6.25063
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PREFORMULATION STUDIES
Ultraviolet (UV) spectrum of drug nizatidine
The solution of nizatidine in 0.1N HCl was screened in the range of 
200–400 nm.
Melting point
The melting point of drug was determined using packing a capillary 
method.
Physical properties of drug powder
The drug nizatidine undergoes through various tests to know its 
physical properties.
Construction of calibration curve
The calibration curve for nizatidine was determined in 0.1N HCl pH 1.2 
in UV spectrophotometer. It is given in Fig. 2.
The flow properties of granules were characterized in terms of angle 
of repose, Carr’s index, Compressibility index, and Hausner ratio. The 
bulk density and tapped density were determined, and from these data, 
Carr’s index and Hausner ratio were calculated [9].
Formulation of mucoadhesive matrix tablet of nizatidine
Matrix tablet of nizatidine was prepared by direct compression method. 
The composition of formulations is shown in Table 2. All the powders 
were passed through a 40 mesh sieve. The batches were prepared by 
mixing the drug, polymer and diluents as given in Table 2. The powder 
blend was lubricated with magnesium stearate and compressed using 
(9 mm diameter round, flat, and plain punches) multiple punch rotary 
tablet machine. In total, 10 formulations containing different amounts 
of HPMC K4M (F1, F2, F3), carbopol-934p (F4, F5, F6), and combination 
of HPMC K4M or carbopol-934p with ethyl cellulose (F7, F8, F9, F10) 
were prepared.
CHARACTERIZATION OF MATRIX TABLETS
Thickness
Five tablets were selected randomly from each batch and were used for 
thickness determination. The thickness of each tablet was measured in 
mm using a digital vernier caliper and their values were reported in 
millimeters. The mean and SD were calculated and reported.
Weight variation test
Ten tablets were selected randomly from each batch and individually 
weighed using an electronic balance. The average weight was calculated. 
The percentage deviation from average weight was reported.
Hardness
The strength of the tablet which prevents from chipping, abrasion or 
breakage under conditions of storage, transportation, and handling 
before usage depends on its hardness. The hardness of five tablets 
which randomly selected from each batch was measured using 
Monsanto hardness tester and expressed in Kg/cm2. The average mean 
and SD were calculated.
Friability
Friability of tablets was performed using Roche friabilator. The tablets 
were carefully de-dusted before testing. Five tablets were randomly 
selected from each batch and accurately weighed. This tablet sample 
was placed in the drum. The drum was rotated 100 times, and the tablets 
were removed,  re-weighed and percentage loss was determined.
Drug content analysis
Five tablets were weighed individually, and the average was calculated 
and grounded in a mortar with a pestle to get fine powder. An amount 
equivalent to 150 mg of the drug was extracted with 100 ml of 0.1 N 
HCl. The drug content was determined by UV spectrophotometer at a 
wavelength 314 nm, and the percentage drug content was calculated.
Swelling index
The swelling of mucoadhesive polymer is an important factor affecting 
adhesion. To carry out the study, a tablet was weighed and placed in a 
Petri dish containing 5 ml of 0.1N HCl buffer pH 1.2 in 10 h at regular 
interval of time (1, 2, 3, 4, 5, 6, 7, 8, 9, 10) and the tablet was taken care 
Table 1: Physical properties of drug
Sr. No Test Result
1 Bulk density (g/ml) 0.443
2 Tap density (g/ml) 0.564
3 Carr’s compressibility 22%
4 Hausner ratio 1.27
5 Angle of repose 31˚
Flow properties Passable
Fig. 1: Nizatidine drug structure
Fig. 2: Calibration curve of nizatidine
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using filter paper. The swelling index was calculated using following 
formula,
Swelling index = [(Weight of swollen tablet - Initial weight of tablet)/
(Initial weight of tablet)] X 100 
Mucoadhesive strength measurement:[10-12]
The mucoadhesive strength of the tablet was measured on the 
modified physical balance (Fig. 3). The apparatus consists of a 
modified double-beam physical balance in which the right and left 
pan has been replaced by lighter pans. The left side of the balance was 
made 5 g heavier than the right side by placing a 5 g weight on left-
side pan. Another Teflon block of 3.8 cm diameter and 2 cm height was 
fabricated with an upward portion of 2 cm height and 1.5 cm diameter 
on one side. This was kept in a beaker, which was then placed below 
the left-hand set of the balance.
The goat gastric mucosa was used as the model membrane, and pH 1.2 
was used as the moistening fluid. The goat gastric mucosa was kept 
in Tyrode solution at 37°C for 2 h. The underlying mucous membrane 
was separated and washed thoroughly with a pH 1.2 solutions. It was 
then tied to Teflon-coated glass slide, and this slide was fixed over the 
protrusion in the Teflon block using a thread. The block was then kept in 
beaker containing pH 1.2 buffer solutions at the level that just touches 
the membrane. By keeping a 5 g weight on the right pan, the two sides 
of the balance were made equal. The beaker with the Teflon block was 
kept below the left-hand setup of the balances. The tablets of each 
batch were struck on to the lower side of the left-hand side pan. The 5 g 
weight from the right pan was then removed. This lowered the left pan 
along with the tablet over the membrane with a weight of 5 g. This was 
kept undisturbed for 5 min. Then, the weight on the right-hand side was 
slowly added in an increment of 0.5 g till the tablet just separated from 
the membrane surface. The excess weight on the right pan, i.e., total 
weight minus 5 g was taken as a measure of the mucoadhesive strength.
From the mucoadhesive strength, the force of adhesion was calculated 
using the following formula:




In vitro drug release study
In vitro drug release studies were performed using the USP dissolution 
apparatus Type II. The drug release profile was studied in 900 ml of 
0.1N HCl buffer of pH 1.2 at 37±0.2°C. The rotational speed of the paddle 
was 50 rpm. Aliquots of 5 ml of dissolution medium were withdrawn at 
specific time intervals, filtered, and replaced with fresh medium. The 
samples were filtered through Whatman filter paper and analyzed after 
appropriate dilution by a UV spectrophotometer (Shimadzu UV 1800) 
at 314 nm, and drug release was determined from the standard curve.
Statistical analysis
To evaluate contribution of each factor with different levels on 
responses, two-way analysis of variance (ANOVA) was performed using 
GraphPad Prism 7.04 software.
RESULTS AND DISCUSSION
Drug excipient compatibility studies
The results showed that the principle IR peak of pure drug and its 
physical mixture with polymer were almost similar, signifying no 
interaction between drug and polymer during formulation of tablets. 
Picture of vials having a drug excipient mixture is shown in Fig. 4.
UV spectrum of drug nizatidine
The solution of Nizatidine in 0.1N HCl was found to exhibit maximum 
absorption (λ max) at 314 nm after scanning in the range of 200–
400 nm. It is given in Fig. 5.
Physical properties of drug powder
Results of physical properties of drug powder are shown in Table 1.
The percent compressibility of the drug was 22% and angle of repose 
was 31˚, suggesting that it can be directly compressed.
Preformulation studies of powders
The prepared powders were characterized for angle of repose, 
bulk density, tapped density, Hausner factor, Carr’s index, and 
Fig. 3: In vitro bioadhesive strength measurement. (a) In vitro bioadhesive strength measurement modified balance apparatus, (b) left 
pan, (c) right pan, (d) teflon cylinder, (e) goat mucosa, (f) threads, (g) beaker containing solution, (h) pointer
Fig. 4: Drug-excipient mixtures in vials
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compressibility index, and the values were reported in Table 3. The 
angle of repose of the different batches of powders was determined 
as per method mentioned earlier, and the results ranged between 
20.005° and 24.38°. The powder with the angle of repose <20° indicates 
excellent flow properties. The bulk densities of powder were ranged 
between 0.300 g/cm3 and 0.428 g/cm3. The low bulk density is due 
to the presence of more fines in the powder. Tapped density ranged 
between 0.360 g/cm3 and 0.521 g/cm3.
EVALUATION OF MATRIX TABLET
Weight variation, thickness, hardness, friability, and drug content 
analysis
Results were represented in Table 4. The diameters of prepared 
tablets were ranged from 9.018 to 9.092. The weights of prepared 
tablets were ranging from 277±13.89 to 295.7±14.78. The thickness of 
prepared tablets was ranged from 3.912 to 4.154. It was also observed 
that increasing the polymer concentration resulted in slight decrease 
in the thickness of tablet formulations. These results indicate that 
the polymers may have highly binding properties. Hardness of tablet 
ranged from 4.834 to 9.5 kg/cm2. For all formulation friability ranged 
from 0.0 to 0.8%, it indicates that friability is within the prescribed limit 
of 1%. The drug content (%) of matrix tablet from each formulation was 
found to be uniform and ranged from 94.19 to 97.41%.
Swelling studies
Swelling index profile of all formulations is shown in Table 5. Swelling 
index of all formulations varies between 172.88 and 455.56%. Swelling 
of the matrix tablet is indicated by the transition of the polymer 
from the glassy to the rubbery state. It is an important parameter in 
determining of the release characteristics of the matrix system. As 
swelling process proceeds, the gel layer gradually becomes thicker, and 
therefore, the drug concentration gradient along the diffusional path 
length is decreased results in the slow drug release.
Measurement of bioadhesion force
The mucoadhesive strength of the tablet was dependent on the property 
of the bioadhesive polymers, which on hydration adhere to the mucosal 
surface and also on the concentration of polymer used. Bioadhesive 
force values ranged from 1.86 to 4.8. Results were represented in 
Table 6 and Fig. 7.
In vitro dissolution studies
All the ten formulations were subjected to in vitro dissolution studies 
using a USP Type II dissolution test apparatus. The dissolution medium 
1.2 pH buffer was used to study the drug release. The samples were 
withdrawn at different intervals of time and analyzed at 314 nm using 
a UV spectrophotometer. The cumulative percentage drug release was 
calculated. The data obtained from in vitro release for formulations 
prepared by direct compression technique are tabulated in Table 7.
From the results, we can conclude that there was increase in the 
extend of duration of drug release with increase in concentration of 
polymer in the formula. From Fig. 8, it can be seen that formulations, 
i.e., F1, F2, and F3 containing 15%, 20%, and 25% of HPMC K4M 
released more than 80% of the drug over 8 h. No difference in release 
Table 2: Composition of mucoadhesive matrix tablet of nizatidine prepared by direct compression
Ingredients F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg) F6 (mg) F7 (mg) F8 (mg) F9 (mg) F10 (mg)
Nizatidine 75 75 75 75 75 75 75 75 75 75
HPMC K4M 45 60 75 - - - 37.5 30 - -
Carbopol-934p - - - 45 60 75 - - 37.5 30
Ethyl cellulose - - - - - - 37.5 45 37.5 45
Microcrystalline cellulose 176 161 146 176 161 146 146 146 146 146
Magnesium stearate 4 4 4 4 4 4 4 4 4 4
Total (mg) 300 300 300 300 300 300 300 300 300 300
Table 3: Physical properties of nizatidine blend with different excipient
Formulation 
code
Bulk density  
(g/ml)










F1 0.353 0.462 23.88 23.52 21.90 1.30
F2 0.428 0.521 22.24 17.80 18 1.217
F3 0.352 0.445 24.38 20.58 20.9 1.264
F4 0.300 0.400 21.75 25 25 1.33
F5 0.300 0.375 21.44 20 20 1.25
F6 0.300 0.360 22.04 17.5 17 1.20
F7 0.352 0.428 20.005 17.64 18.2 1.21
F8 0.363 0.428 23.85 15.15 16 1.179
F9 0.333 0.413 21.55 19.44 20 1.24
F10 0.352 0.413 21.31 14.70 15 1.17
Table 4: Post-compression parameters of mucoadhesive matrix tablets of nizatidine
Formulation 
code
Diameter* (mm) Thickness* (mm) Hardness* (kg/cm2) Friability (%) % Weight variation^ % drug content#
F1 9.046±0.011 4.154±0.009 4.834±0.289 0.7 289±7.397 95.07±0.375
F2 9.092±0.013 4.14±0.07 5.5±0.00 0.7 280±9.428 96.77±0.416
F3 9.068±0.008 4.12±0.020 5.834±0.289 0.7 295.7±4.347 93.99±0.00
F4 9.06±0.016 3.974±0.013 6.34±0.289 0.7 292.4±4.164 94.86±0.375
F5 9.04±0.010 3.926±0.011 7.67±0.289 0 295±4.346 96.76±0.393
F6 9.04±0.012 3.912±0.008 8.34±0.289 0.8 295.6±4.274 96.56±0.640
F7 9.046±0.009 4.02±0.010 8±0.00 0.7 287±4.275 95.93±0.00
F8 9.032±0.013 4.018±0.008 8.5±0.00 0.7 283.6±4.575 96.98±0.393
F9 9.018±0.008 4.026±0.015 9±0.00 0 277.8±3.938 96.56±0.640
F10 9.028±0.008 4.016±0.005 9.5±0.00 0 279.1±6.385 94.21±0.375
*All values expressed in mean±SD, n=5. ^All value expressed in mean±SD, n=10. #All value expressed in mean±SD, n=3. SD: Standard deviation
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Fig. 5: Ultraviolet spectrum of nizatidine
Table 5: Swelling index study of all formulations
Time % F1 %F2 %F3 %F4 %F5 %F6 %F7 %F8 %F9 %F10
0 0 0 0 0 0 0 0 0 0 0
1 87.29 85.23 78.08 146.18 115.57 112.07 104.41 93.22 104.73 110.88
2 111.71 114.77 114.04 146.18 142.91 141.03 128.14 102.71 130.41 126.67
3 122.74 132.55 120.89 177.08 159.52 147.59 138.98 106.78 138.51 144.91
4 164.88 164.43 156.85 189.93 176.12 156.55 152.88 116.61 151.69 145.96
5 170.90 173.49 173.29 214.24 197.58 178.97 169.83 123.05 166.22 155.44
6 211.04 209.06 188.36 245.83 242.56 229.66 173.90 133.22 171.96 166.67
7 219.73 217.11 203.42 262.85 253.63 244.14 186.78 143.73 182.43 174.39
8 231.10 234.23 215.75 316.67 302.08 279.31 204.41 157.63 195.95 180.35
9 236.12 235.91 239.38 425.35 350.17 292.07 215.25 170.85 203.72 182.46
10 265.22 244.97 242.81 455.56 363.32 338.97 220.34 172.88 204.73 190.88
rate was observed between tablets containing either 15% and 20% of 
HPMC K4M. Drug release decreased significantly in the formulation 
containing 25% of HPMC K4M. It can be seen that formulations, 
i.e., F4, F5, and F6 (Fig. 9) loaded with 15%, 20%, and 25% of the 
carbopol-934P released over 90% of the drug over 4 h, 6 h, and 6 h, 
respectively. Tablets containing 25% of carbopol-934p were able to 
form the gelatinous layer around the tablet core, and the drug release 
was found to be 95.55% within 6 h of dissolution study. Therefore, in 
order to control the initial burst release, ethyl cellulose was included 
in the matrix of the next batch of tablets in the ratio of 1:1 along with 
HPMC K4M (F7) or carbopol-934p (F9) which resulted in extending 
the drug release for a period of 12 h indicating fair uniform drug 
release throughout the dissolution period. This may be due to a more 
rigid, complex structure formed by hydrophilic polymers (HPMC K4M 
and carbopol-934p) in the presence of ethyl cellulose, which helped 
in retaining the drug in the matrix and hindering rapid diffusion of 
soluble drug from the matrix. Increasing the concentration of ethyl 
cellulose shows more retardation in the release of the drug from the 
formulations, i.e., F8 and F10 containing ethyl cellulose in combination 
with HPMC K4M and carbopol-934p in the ratio 1:1.5, respectively. 
F8 showed 56.13% and F10 showed only 60.35% of drug release in 
12 h of dissolution study, which may result in therapeutic failure of 
the formulation. As shown in Fig. 10 and Fig. 11.
CONCLUSION
In the present work, an attempt has been made formulating 
mucoadhesive matrix tablets of nizatidine using various hydrophilic 
polymers such as HPMC K15M, carbopol-934P, and hydrophobic 
Fig. 6: Swelling index of all formulations (F1-F10)
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Fig. 7: Mucoadhesive test for all formulations (F1-10)
Fig. 8: In vitro drug release profile of nizatidine tablets made from HPMC K4M polymer
Table 7: In vitro drug release of all formulations (% cumulative release)
Time F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
0 0 0 0 0 0 0 0 0 0 0
0.5 14.28 11.92 1.33 21.33 21.33 15.45 0.16 -1.02 0.16 -1.02
1 35.53 31.99 4.87 33.22 33.22 27.30 1.33 1.33 1.33 0.15
2 44.17 38.23 33.25 45.17 45.17 45.10 4.87 3.69 6.05 2.51
3 50.31 39.62 45.20 68.94 57.18 63.00 8.43 8.41 8.43 7.23
4 51.76 45.72 63.40 95.21 71.61 79.81 12.00 15.52 20.25 9.61
6 69.68 75.38 77.86 - 94.36 95.55 27.36 20.31 29.77 20.21
8 91.24 87.56 82.99 - - - 43.99 31.01 54.64 27.33
10 - - - - - - 63.05 44.12 74.94 35.60
12 - - - - - - 83.40 56.13 94.18 60.35
Table 6: Bioadhesive force of all formulations











polymers such as ethyl cellulose. Mucoadhesive matrix tablet of 
nizatidine was prepared by direct compression method. In vitro 
dissolution studies of ten batches concluded that the batch F1, F2, 
and F3 tablets completely disintegrated at 8 h and batch F4, F5, 
and F6 completely disintegrated at 4, 6, and 6 h, respectively, so 
these batches were rejected. Among the other batches, F9 batch 
was selected as an optimized batch because the pre- and post-
compression parameter results are satisfactory. The F9 batch showed 
best result as the percent cumulative drug release of F9 is 94.18% at 
12 h, and also, the % swelling index is about 204.73% at 10 h. The 
tablet does not swell too much, which results in controlled release of 
the drug and also shows good bioadhesive strength in acidic media.
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Fig. 9: In vitro drug release profile of nizatidine tablets made from carbopol-934p polymer
Fig. 10: In vitro drug release profile of nizatidine tablets made from HPMC K4M and ethyl cellulose polymer
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